Remibrutinib + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren Syndrome
Conditions
Sjögren Syndrome
Trial Timeline
Jul 12, 2019 → Nov 23, 2021
NCT ID
NCT04035668About Remibrutinib + Placebo
Remibrutinib + Placebo is a phase 2 stage product being developed by Novartis for Sjögren Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04035668. Target conditions include Sjögren Syndrome.
What happened to similar drugs?
0 of 8 similar drugs in Sjögren Syndrome were approved
Approved (0) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06865651 | Phase 2 | Recruiting |
| NCT05432388 | Phase 2 | Completed |
| NCT04035668 | Phase 2 | Terminated |
Competing Products
20 competing products in Sjögren Syndrome